

## 36<sup>th</sup> World Cardiology Conference; 29<sup>th</sup> International Conference on Cardiology and Cardiovascular Diseases

Efficacy and Safety of Ticagrelor in Comparison with Clopidogrel in Elderly Patients with Stable Coronary Disease after Percutaneus Coronary Reperfusion.

V.Vasilakopoulos<sup>1</sup>, S. Theodoridou<sup>1</sup>, P. Roditis<sup>1</sup>, G. Papagoras<sup>1</sup>, E. Kipirtidou<sup>1</sup>, Chr.Tsoumis<sup>1</sup>, An. Papanastasiou<sup>2</sup>, P. Xaras<sup>2</sup>, D. Semizoglou<sup>2</sup>, S. Lampropoulos<sup>1</sup>.

Kozani General Hospital- Cardiology Department<sup>1</sup>- Department of Internal Medicine<sup>2</sup>

**Introduction:** Current guidelines recommend Clopidogrel for patients with stable coronary heart disease after percutaneous coronary.

**Purpose:** This study was designed to investigate the efficacy and safety of Ticagrelor compared with conventional Clopidogrel treatment in elderly patients with stable coronary heart disease who underwent coronary transdermal reperfusion.

Material - Methods: We studied 323 patients (206 men, mean age 83.2 years) with stable coronary heart disease, during the four years 2015-2019, aged ≥75 years who underwent angioplasty. The complex primary endpoints were death, myocardial infarction, and stroke. Safety was assessed from the occurrence of any significant bleeding event within 1 year. We studied 1087 consecutive patients with stable coronary heart disease (206 men, mean age 83.2 years) who underwent invasive reperfusion. 164 received clopidogrel and 159 received ticagrelor.

**Results:** The primary endpoint occurred in 18.4% of patients treated with clopidogrel versus 13.6% of those receiving ticagrelor (p = 0.015), with a 1-year mortality rate of 17.1% versus 12.4% (p = 0.035). Bleeding events were rare and did not differ statistically significantly between the two groups. Conclusions: The above results indicate that for elderly patients with stable coronary heart disease undergoing invasive reperfusion, ticagrelor compared with clopidogrel was associated with a reduction in severe adverse cardiovascular events without a significant increase in bleeding events.

## Biography

V.Vasilakopoulos is a Doctor working in the Kozani General Hospital in the Cardiology Department, Greece. His area of expertise is Cardiology, Internal Medicine. He has served as an peer-reviewed editor for several reputed journals and also published several research papers in the international journals.

Journal of Metabolic Syndrome Volume 10
ISSN: 2167-0943